Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody

By Deniz Yamo   Gupta Niroo  

Clinical Reviews in Allergy and Immunology, Vol. 29, Iss. 1, 2005-02 ,pp. : 31-48

Humana Press, Inc

Access to resources Recommend Favorite

Tolerability of Retreatment with Omalizumab, a Recombinant Humanized Monoclonal Anti-IgE Antibody, during a Second Ragweed Pollen Season in Patients with Seasonal Allergic Rhinitis

By Nayak Anjuli   Casale Thomas   Miller S. David   Condemi John   McAlary Margaret   Fowler-Taylor Angel   Della Cioppa Giovanni   Gupta Niroo  

Allergy and Asthma Proceedings, Vol. 24, Iss. 5, 2003-09 ,pp. : 323-329

OceanSide Publications, Inc

Access to resources Recommend Favorite

Considerations for in vitro monoclonal antibody production

By Peterson N.C.  

Research in Immunology, Vol. 149, Iss. 6, 1998-07 ,pp. : 553-557

Elsevier

Access to resources Recommend Favorite

Monoclonal antibody production: problems and solutions

By Falkenberg F.W.  

Research in Immunology, Vol. 149, Iss. 6, 1998-07 ,pp. : 542-547

Elsevier

Access to resources Recommend Favorite

Monoclonal antibody mechanisms of action in cancer

By Weiner George  

Immunologic Research, Vol. 39, Iss. 1-3, 2007-11 ,pp. : 271-278

Humana Press, Inc

Access to resources Recommend Favorite